公开(公告)号：EP2697654A4

公开(公告)日：2014-11-12

申请号：EP12770850

申请日：2012-04-13

申请人： HYTEST LTD

发明人： KATRUKHA ALEXEY G ,  POSTNIKOV ALEXANDER B ,  SMOLYANOVA TATIANA I ,  KHARITONOV ALEXEY V ,  TAMM NATALIA N

IPC分类号： G01N33/68 ,  A61K38/30 ,  A61P9/00

CPC分类号： G01N33/6893 ,  A61K38/1754 ,  G01N2333/4745 ,  G01N2800/2871 ,  G01N2800/32 ,  G01N2800/52 ,  G01N2800/60

摘要： The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

公开(公告)号：EP2763687A1

公开(公告)日：2014-08-13

申请号：EP11866584.3

申请日：2011-07-06

申请人： Biocure Pharma, LLC

发明人： OH, Youngman

IPC分类号： A61K38/00 ,  A61K39/395

CPC分类号： A61K39/3955 ,  A61K35/28 ,  A61K35/35 ,  A61K35/761 ,  A61K38/1709 ,  A61K38/1754 ,  A61K2039/505 ,  C07K16/2869 ,  C07K2317/75

摘要： Compositions comprising IGFBP-3 receptor agonists and methods for the treatment of metabolic syndrome, obstructive respiratory disorders, obstructive or inflammatory respiratory disease, cancers and related diseases with IGFBP-3 receptor agonists are presented. A method for interfering with the activity of nuclear factor-kappaB (NF-KB) in a cell, comprising: providing to a cell an effective amount of a composition comprising an IGFBP-3 receptor agonist; and interfering with the activity of NF-KB in the cell is included.

公开(公告)号：EP2462945A2

公开(公告)日：2012-06-13

申请号：EP12157644.1

申请日：2007-08-16

申请人： National Research Council of Canada

发明人： Moreno, Maria J.

IPC分类号： A61K38/57 ,  A61K38/30 ,  A61P35/00 ,  C07K14/65 ,  C07K14/81 ,  C12N9/64

CPC分类号： A61K38/1754 ,  A61K38/00 ,  C07K14/4743

摘要： Insulin-like growth factor binding proteins (IGFBPs) and variants thereof, including IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6 and the C-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin B activity.

摘要翻译： 胰岛素样生长因子结合蛋白（的IGFBPs）及其变体，包括IGFBP-1，IGFBP-2，IGFBP-3，IGFBP-4，IGFBP-5，IGFBP-6并且其C-末端片段，抑制血管生成，肿瘤发生 和组织蛋白酶活性，特别是组织蛋白酶B的活性。

公开(公告)号：EP1486565B1

公开(公告)日：2007-11-21

申请号：EP04019502.6

申请日：1996-09-27

申请人： Novartis Vaccines and Diagnostics, Inc.

发明人： Williams, Lewis T.

IPC分类号： C12N15/12 ,  C12N15/16 ,  A61K38/17 ,  A61K38/18 ,  A61K38/30

CPC分类号： C07K14/49 ,  A61K9/06 ,  A61K9/127 ,  A61K9/4825 ,  A61K9/7015 ,  A61K38/00 ,  A61K38/1754 ,  A61K38/1825 ,  A61K38/30 ,  A61K48/00 ,  A61L26/0047 ,  A61K2300/00

公开(公告)号：EP3077819A1

公开(公告)日：2016-10-12

申请号：EP14868424.4

申请日：2014-12-03

申请人： Astute Medical, Inc. ,  University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： MCPHERSON, Paul ,  KELLUM, John, A.

IPC分类号： G01N33/566

CPC分类号： A61K38/13 ,  A61K31/357 ,  A61K31/366 ,  A61K31/436 ,  A61K31/437 ,  A61K31/453 ,  A61K31/55 ,  A61K31/585 ,  A61K38/1754 ,  A61K38/55 ,  A61K45/06 ,  G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/50

摘要： It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G
0 /G
1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G
0 /G
1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

摘要翻译： 它是本发明的一个目的是通过治疗受试者与化合物做调节细胞周期以提供用于从急性肾损伤的受试者的保护方法和组合物。 调节细胞周期可以包括诱导G0 / G1期细胞周期停滞和/或诱导细胞周期进程。 如以下实例阐述，其诱导G0 / G1细胞周期阻滞可以保护受试者从AKI，并且可以提前的预防性使用，或作为治疗以下的化合物的甚至单次给药，各种处理或条件也已知是有害 肾脏，通过逮捕任选发行紧随其后。 一旦AKI被建立，细胞周期进程可以被诱导以增加替换丢失和损坏细胞的

公开(公告)号：EP2148695B1

公开(公告)日：2014-10-15

申请号：EP08779242.0

申请日：2008-04-18

申请人： Premacure AB

发明人： HELLSTRÖM, Ann ,  LÖFQVIST, Chatarina ,  SMITH, Lois

IPC分类号： A61K38/30 ,  A61K38/17

CPC分类号： A61K38/30 ,  A61K38/1709 ,  A61K38/1754 ,  A61K2300/00

公开(公告)号：EP1648494A2

公开(公告)日：2006-04-26

申请号：EP04786012.7

申请日：2004-07-30

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： PLOUET, Jean ,  LAURENT-BEUBRY, Maryvonne ,  MARTINERIE-KRYCEVE, Cécile

IPC分类号： A61K38/18 ,  A61P35/00 ,  A61P17/00 ,  A61P19/02 ,  A61P27/02 ,  A61P37/06

CPC分类号： A61K38/1754

摘要： The invention concerns the use of a protein characterized in that it comprises or consists of the NOV protein, represented by the sequence SEQ ID NO: 2, or a fragment of said protein, provided that said fragment exhibits an angiogenesis inhibiting activity, or any sequence derived from the sequence SEQ ID NO: 2 or a fragment as defined above, provided that said derived sequence exhibits an angiogenesis inhibiting activity, or any sequence homologous of the sequence SEQ ID NO: 2 or a fragment as defined above, provided that said homologous sequence exhibits an angiogenesis inhibiting activity, for preparing a medicine for treating pathologies requiring inhibition of endothelial proliferation or pathologies requiring inhibition of endothelial activation.

公开(公告)号：EP0871730B1

公开(公告)日：2004-08-18

申请号：EP96933952.2

申请日：1996-09-27

申请人： CHIRON CORPORATION

发明人： WILLIAMS, Lewis, T.

IPC分类号： C12N15/12 ,  C12N15/16 ,  A61K38/17 ,  A61K38/18 ,  A61K38/30

CPC分类号： C07K14/49 ,  A61K9/06 ,  A61K9/127 ,  A61K9/4825 ,  A61K9/7015 ,  A61K38/00 ,  A61K38/1754 ,  A61K38/1825 ,  A61K38/30 ,  A61K48/00 ,  A61L26/0047 ,  A61K2300/00

摘要： The invention provides a therapeutic composition for epithelial wound repair that is a combination of PDGF and KGF. Further, the invention provides a composition for epithelial wound repair that is a therapeutic combination of PDGF, KGF and IGF. Additionally, the invention provides a therapeutic composition of PDGF, KGF, IGF and IGFBP for epithelial wound repair.

公开(公告)号：EP0444081B1

公开(公告)日：1999-05-12

申请号：EP89912690.8

申请日：1989-11-17

申请人： PRISELL, Per ,  NORSTEDT, Gunnar

发明人： PRISELL, Per ,  NORSTEDT, Gunnar

IPC分类号： A61K9/22 ,  A61K47/00 ,  A61K38/00 ,  A61K38/27

CPC分类号： A61K9/0024 ,  A61K9/204 ,  A61K31/728 ,  A61K38/1754 ,  A61K38/1796 ,  A61K38/30 ,  A61K47/50 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/595 ,  A61K47/61 ,  A61K47/642 ,  A61K47/6849 ,  A61K2300/00

摘要： This invention relates to a pharmaceutical preparation comprising a combination of one or several receptor/binding proteins (binding growth factors or hormones) and hyaluronic acid (or its derivatives) or a biodegradable polymer, optionally in combination with its/their ligands (growth factors and hormones).

公开(公告)号：EP0871730A1

公开(公告)日：1998-10-21

申请号：EP96933952.0

申请日：1996-09-27

申请人： CHIRON CORPORATION

发明人： WILLIAMS, Lewis, T.

IPC分类号： C12N15 ,  A61K31 ,  A61K38 ,  A61P17 ,  C07H21 ,  C07K14 ,  A61K48

CPC分类号： C07K14/49 ,  A61K9/06 ,  A61K9/127 ,  A61K9/4825 ,  A61K9/7015 ,  A61K38/00 ,  A61K38/1754 ,  A61K38/1825 ,  A61K38/30 ,  A61K48/00 ,  A61L26/0047 ,  A61K2300/00

摘要： The invention provides a therapeutic composition for epithelial wound repair that is a combination of PDGF and KGF. Further, the invention provides a composition for epithelial wound repair that is a therapeutic combination of PDGF, KGF and IGF. Additionally, the invention provides a therapeutic composition of PDGF, KGF, IGF and IGFBP for epithelial wound repair.